Enough doses coming despite EU, says govt
As the EU threatens a ban on exports of coronavirus vaccines from the bloc, authorities in Australia stick to a late-February rollout.
Csl
Jab in the arm: The art of the passive aggressive email
We have all sent and received them, but CSL’s director of public policy and government relations gave us an email refresher course.
AstraZeneca CEO leaves CSL board
AstraZeneca’s Pascal Soriot will resign as a director of CSL over a potential conflict of interest with a corporate acquisition.
Aussie vaccine production hopes dented
The Novavax COVID-19 jab won’t be produced in Australia until 50 million AstraZeneca doses have been made, in a blow to Australia vaccine hopes.
Three-month wait for local vaccines
Australians will have to wait at least another three months to be injected with the first locally produced COVID-19 vaccine, as manufacturer CSL says it will not ‘fast-track’ production.
Watkins, Hewson on board for Reserve Bank’s fight back
Alison Watkins and Carolyn Hewson have been appointed as members to the Reserve Bank board.
HIV, Covid and fake news a deadly cocktail
Putting the two biggest health crises in the past 30 years – HIV and COVID-19 – in the same sentence was never going to end well.
Risk on vaccine was too much: CSL
Hopes of bolstering lucrative royalties and licence revenue from the development of a homegrown COVID-19 vaccine have been dashed.
ASX extends losses as CSL setback weighs
Stocks at five-day low following wobble on Wall Street, as CSL lost 3pc after vaccine trials were halted and IGO jumped after a raising.
Harness the best of the crisis
The need for a robust, sustainably funded scientific community has never been stronger, says CSL chief Paul Perrault.
ASX slips lower with banks, CSL down
The ASX again slipped lower, with the big surprise being CSL’s hopes of producing a locally developed COVID-19 vaccine dashed.
CSL knew of ‘risk’ to vaccine trials
Researchers considered the potential for false HIV positives in the COVID-19 vaccine a ‘manageable risk’. But trials have now been halted.
ASX on seven-day winning streak
The ASX winning streak has continued for a seventh straight day, with health stocks and Commonwealth Bank among the winners.
Cochlear boss likes sound of new CSL plant
Cochlear’s CEO Dig Howitt says the federal government’s $1.8bn deal with CSL will build Australia’s competitive advantage in medical manufacturing.
CSL plans $1.8bn vaccine factory
CSL’s influenza vaccine business, Seqirus, struck a $1.8bn deal with the Morrison government to build the factory.
Melbourne scores major vaccine coup
A new $1.8 billion vaccine manufacturing plant is set to be built in Melbourne to help secure the nation against future pandemics and flu seasons.
New vaccine plant builds on our scientific strengths
The nation will be well placed to fight future pandemics.
Vaccine plant to supply nation
Southern hemisphere’s largest vaccine manufacturing plant to be built in Australia in a $1.8bn deal.
Biggest health stock ‘still underrated’
Paradice’s David Moberley is excited about the “game-changing” opportunities for Australia’s foremost health care stock.
Australia’s plasma monopoly is stifling biotech
Our company is on the cusp of commercialising a COVID-19 hyperimmune treatment, but we are being forced to source plasma from overseas.
Original URL: https://www.theaustralian.com.au/topics/csl/page/11